<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095873</url>
  </required_header>
  <id_info>
    <org_study_id>PJT_HATFF</org_study_id>
    <secondary_id>TSB101129</secondary_id>
    <nct_id>NCT02095873</nct_id>
  </id_info>
  <brief_title>Healthy Aging Through Functional Food</brief_title>
  <acronym>HATFF</acronym>
  <official_title>Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technology Strategy Board, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Warwick</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dietary inducers of glyoxalase 1 are
      effective in improving metabolic and vascular health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate dietary inducers of glyoxalase 1 for effects on metabolic
      and vascular health in overweight volunteers at risk of developing type 2 diabetes. The
      research objectives are:

      (i) To evaluate dietary inducers of glyoxalase 1 for effects on markers of glucose metabolism
      during an oral glucose tolerance test (oGTT), (ii) To evaluate dietary inducers of glyoxalase
      1 for effects on vascular function on three levels, using finger fold capillary density by
      capillaroscopy (FFCD), arterial stiffness by aortal pulse wave velocity (aPWV) and flow
      mediated dilatation (FMD); and effects on metabolic and pro-inflammatory markers in
      circulating blood and urine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve for Oral Glucose Tolerance Test (oGGT)</measure>
    <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
    <description>A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (&gt; 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Finger-fold Capillary Density by Capillaroscopy</measure>
    <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
    <description>After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated Dilatation (FMD)</measure>
    <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
    <description>Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Aortal Pulse Wave Velocity (aPWV)</measure>
    <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
    <description>Aortal pulse wave velocity is measured by a non-invasive oscillometric device.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Aortic Stiffness</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Glo1-inducer then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Glo1-inducer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glyoxalase 1 (Glo1) inducer</intervention_name>
    <description>Dietary bioactive</description>
    <arm_group_label>Glo1-inducer then placebo</arm_group_label>
    <arm_group_label>Placebo then Glo1-inducer</arm_group_label>
    <other_name>trans-resveratrol, 90 mg + hesperetin, 120 mg (combination)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol, 108 mg</description>
    <arm_group_label>Glo1-inducer then placebo</arm_group_label>
    <arm_group_label>Placebo then Glo1-inducer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 25 - 40 kg/m2 (&gt;23 kg/m2 for Asians), with normal, impaired fasting or impaired
             postprandial glucose.

          -  No other relevant morbidities.

          -  Women will be preferably post-menopausal.

        Exclusion Criteria:

          -  Severe hypertriglyceridemia.

          -  Uncontrolled hypertension, cardiovascular disease, relevant renal or hepatic disease,
             diabetes, and other relevant morbidity.

          -  Excess alcohol consumption, smoking, acute pharmacological treatment with drugs
             affecting glucose metabolism such as steroids and antibiotics.

          -  Anticoagulants.

          -  Intake of herbal remedies.

          -  Food allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Thornalley, BSc PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Warwick</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin O Weickert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Coventry &amp; Warwickshire NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire NHS Trust (UHCW)</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV22DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, Park BK, Souma T, Moriguchi T, Yamamoto M, Thornalley PJ. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J. 2012 Apr 1;443(1):213-22. doi: 10.1042/BJ20111648.</citation>
    <PMID>22188542</PMID>
  </reference>
  <reference>
    <citation>Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun. 2015 Mar 6;458(2):221-6. doi: 10.1016/j.bbrc.2015.01.140. Epub 2015 Feb 7. Review.</citation>
    <PMID>25666945</PMID>
  </reference>
  <results_reference>
    <citation>Xue M, Weickert MO, Qureshi S, Kandala NB, Anwar A, Waldron M, Shafie A, Messenger D, Fowler M, Jenkins G, Rabbani N, Thornalley PJ. Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes. 2016 Aug;65(8):2282-94. doi: 10.2337/db16-0153. Epub 2016 May 11.</citation>
    <PMID>27207552</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>August 2, 2016</results_first_submitted>
  <results_first_submitted_qc>January 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 15, 2017</last_update_submitted>
  <last_update_submitted_qc>January 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warwick</investigator_affiliation>
    <investigator_full_name>Professor Paul J. Thornalley</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Oral glucose tolerance test</keyword>
  <keyword>Flow mediated dilatation</keyword>
  <keyword>Aortal pulse wave velocity</keyword>
  <keyword>Finger-fold capillary density by capillaroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glyoxalase 1 Inducer First, Then Placebo</title>
          <description>Glyoxalase 1 inducer (capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin combination) once daily, 8 weeks; then Placebo (excipient: Mannitol, 108 mg) once daily, 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Glyoxalase 1 Inducer</title>
          <description>Placebo (excipient: Mannitol, 108 mg), once daily, 8 weeks; then Glyoxalase 1 inducer (capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin combination) once daily, 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glyoxalase 1 Inducer Then Placebo</title>
          <description>Glyoxalase 1 inducer (90 mg trans-resveratrol &amp; 120 mg hesperetin), once daily, 8 weeks; then Placebo (excipient: 108 mg mannitol), once daily, 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Glyoxalase 1 Inducer</title>
          <description>Placebo (excipient: 108 mg mannitol), once daily, 8 weeks; then Glyoxalase 1 inducer (90 mg trans-resveratrol &amp; 120 mg hesperetin), once daily, 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="12"/>
                    <measurement group_id="B2" value="44" spread="13"/>
                    <measurement group_id="B3" value="45" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for Oral Glucose Tolerance Test (oGGT)</title>
        <description>A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (&gt; 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.</description>
        <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
        <population>Highly overweight/obese (BMI&gt;27.5 kg/m2) subgroup, based on subject BMI at study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Glyoxalase 1 Inducer</title>
            <description>Glyoxalase 1 inducer (90 mg trans-resveratrol &amp; 120 mg hesperetin), once daily, 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (excipient: 108 mg mannitol), capsule, once daily, 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Oral Glucose Tolerance Test (oGGT)</title>
          <description>A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (&gt; 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.</description>
          <population>Highly overweight/obese (BMI&gt;27.5 kg/m2) subgroup, based on subject BMI at study entry.</population>
          <units>mM h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="0.7"/>
                    <measurement group_id="O2" value="11.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-8 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="0.6"/>
                    <measurement group_id="O2" value="10.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Finger-fold Capillary Density by Capillaroscopy</title>
        <description>After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements.</description>
        <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
        <population>All subjects with where baseline and post-8 treatment data were obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Glyoxalase 1 Inducer</title>
            <description>Glyoxalase 1 inducer (capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin combination) once daily, 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (excipient: Mannitol, 108 mg), once daily, 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Finger-fold Capillary Density by Capillaroscopy</title>
          <description>After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements.</description>
          <population>All subjects with where baseline and post-8 treatment data were obtained.</population>
          <units>number of capillaries per mm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="90" upper_limit="140"/>
                    <measurement group_id="O2" value="119" lower_limit="107" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-8 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="88" upper_limit="169"/>
                    <measurement group_id="O2" value="128" lower_limit="104" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flow-mediated Dilatation (FMD)</title>
        <description>Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion.</description>
        <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
        <population>All subjects completing the study per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Glyoxalase 1 Inducer</title>
            <description>Glyoxalase 1 inducer (capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin combination) once daily, 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (excipient: Mannitol, 108 mg), once daily, 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Dilatation (FMD)</title>
          <description>Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion.</description>
          <population>All subjects completing the study per protocol</population>
          <units>percentage of baseline value</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.10" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.07" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-8 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.06" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.07" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Aortal Pulse Wave Velocity (aPWV)</title>
        <description>Aortal pulse wave velocity is measured by a non-invasive oscillometric device.</description>
        <time_frame>Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)</time_frame>
        <population>Subjects for which PWV data were obtained at baseline and post 8-weeks treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Glyoxalase 1 Inducer</title>
            <description>Glyoxalase 1 inducer (capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin combination) once daily, 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (excipient: Mannitol, 108 mg), once daily, 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortal Pulse Wave Velocity (aPWV)</title>
          <description>Aortal pulse wave velocity is measured by a non-invasive oscillometric device.</description>
          <population>Subjects for which PWV data were obtained at baseline and post 8-weeks treatment.</population>
          <units>m/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="7.1" upper_limit="8.8"/>
                    <measurement group_id="O2" value="8.3" lower_limit="7.4" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-8 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.1" upper_limit="10.0"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7.5" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to study completion: 8 weeks Glo1-inducer, 6 weeks washout then 8 weeks placebo; or 8 weeks placebo, 6 weeks washout then 8 weeks Glo1-inducer.</time_frame>
      <desc>All potential clinical adverse effects were monitoring including nausea, loss of appetite, gastrointestinal side effects and other symptoms. Clinical chemistry and haematological assessments were also made.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glo1-inducer Then Placebo</title>
          <description>Glyoxalase 1 inducer: capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin, once daily for 8 weeks; then 6-weeks washout; then placebo capsule (mannitol, 210 mg), once daily for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Then Glo1-inducer</title>
          <description>Placebo capsule (mannitol, 210 mg), once daily for 8 weeks; then 6-weeks washout; then Glyoxalase 1 inducer: capsule, 90 mg trans-resveratrol &amp; 120 mg hesperetin, once daily for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul J Thornalley</name_or_title>
      <organization>University of Warwick</organization>
      <phone>+442476968594</phone>
      <email>P.J.Thornalley@warwick.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

